Table 1.
Synergetic effect of miR-182 and FOXO3a on predicting CRC progression.
| FOXO3aa | miR-182a |
||
|---|---|---|---|
| Low % of Stage III/IV (n) |
High % of Stage III/IV (n) |
Total % of Stage III/IV (n) |
|
| Low | 100% (6) | 50% (4) | 80% (10) |
| High | 50% (4) | 16.7% (6) | 30% (10) |
| Total | 80% (10) | 30% (10) | 55% (20) |
Based on the cut-point of median relative expressions (2.02 for miR-182 and 0.21 for FOXO3a), Fisher's exact test P = 0.024 for testing four sub-groups with tumor stage.